IFNA1 and juvenile dermatomyositis: In recent years, some case reports have indicated that a JAK inhibitor is highly effective in treating JDM-associated ILD, with a combined effect of IFN signaling down-regulation and reduced expressions of proinflammatory cytokines (13, 16, 28–32).